A first-in-human study of KY1044, a fully human anti-ICOS IgG1 antibody as monotherapy and in combination with atezolizumab in patients with selected advanced malignancies.

Sonia Quaratino,Richard C.A. Sainson,Anil K. Thotakura,Simon J. Henderson,Kerstin Pryke,Anthea Newton,Nuala Brennan,Elisabeth Oelmann

A first-in-human study of KY1044, a fully human anti-ICOS IgG1 antibody as monotherapy and in combination with atezolizumab in patients with selected advanced malignancies.

2019

Sonia Quaratino
Richard C.A. Sainson
Anil K. Thotakura
Simon J. Henderson
Kerstin Pryke
Anthea Newton
Nuala Brennan
Elisabeth Oelmann

TPS2644Background: The Inducible T-cell costimulator (ICOS/CD278) is related to the CD28 superfamily and is induced upon T cell activation. There is a hierarchical order of ICOS expression level, i...

Keywords:

Human study
Pathology
Oncology
Antibody
Atezolizumab
Internal medicine
Medicine
T cell
CD28
SUPERFAMILY
CD278
first in human
Cancer research
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations